IL325384A - Engineered aav capsid proteins - Google Patents

Engineered aav capsid proteins

Info

Publication number
IL325384A
IL325384A IL325384A IL32538425A IL325384A IL 325384 A IL325384 A IL 325384A IL 325384 A IL325384 A IL 325384A IL 32538425 A IL32538425 A IL 32538425A IL 325384 A IL325384 A IL 325384A
Authority
IL
Israel
Prior art keywords
capsid proteins
aav capsid
engineered aav
engineered
proteins
Prior art date
Application number
IL325384A
Other languages
Hebrew (he)
Original Assignee
UCB Biopharma SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UCB Biopharma SRL filed Critical UCB Biopharma SRL
Publication of IL325384A publication Critical patent/IL325384A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IL325384A 2023-07-03 2025-12-16 Engineered aav capsid proteins IL325384A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363511793P 2023-07-03 2023-07-03
PCT/EP2024/068552 WO2025008323A1 (en) 2023-07-03 2024-07-02 Engineered aav capsid proteins

Publications (1)

Publication Number Publication Date
IL325384A true IL325384A (en) 2026-02-01

Family

ID=91853417

Family Applications (1)

Application Number Title Priority Date Filing Date
IL325384A IL325384A (en) 2023-07-03 2025-12-16 Engineered aav capsid proteins

Country Status (7)

Country Link
KR (1) KR20260034663A (en)
CN (1) CN121712809A (en)
AR (1) AR133153A1 (en)
AU (1) AU2024290842A1 (en)
IL (1) IL325384A (en)
TW (1) TW202507010A (en)
WO (1) WO2025008323A1 (en)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201310544D0 (en) 2013-06-13 2013-07-31 Ucb Pharma Sa Obtaining an improved therapeutic ligand
ES2865487T3 (en) 2015-09-28 2021-10-15 Univ North Carolina Chapel Hill Methods and compositions for viral vectors that evade antibodies
WO2017212019A1 (en) 2016-06-09 2017-12-14 Centre National De La Recherche Scientifique (Cnrs) Raav with chemically modified capsid
CA3053154A1 (en) * 2017-06-30 2019-01-03 The Regents Of The University Of California Adeno-associated virus virions with variant capsids and methods of use thereof
EP3728568A4 (en) 2017-12-19 2021-10-06 The University of North Carolina at Chapel Hill METHODS AND COMPOSITIONS FOR THE ADMINISTRATION OF VIRAL VECTORS ACROSS THE HAEMATOENCEPHALIC BARRIER
US20210363193A1 (en) 2018-04-27 2021-11-25 Universität Heidelberg Modified aav capsid polypeptides for treatment of muscular diseases
EP3564263A1 (en) 2018-05-03 2019-11-06 Universitätsklinikum Hamburg-Eppendorf Fusion proteins comprising a cell surface marker specific vhh
US20190390628A1 (en) 2018-06-25 2019-12-26 Leading Edge V-Twin LLC Methods and apparatus for an actively cooled cylinder block
EP3715358A1 (en) 2019-03-28 2020-09-30 Universität zu Köln Mutated adeno-associated virus capsid proteins, aav particle comprising the same and liver directed aav vector gene therapy
IL296732A (en) 2020-03-27 2022-11-01 UCB Biopharma SRL Autonomous knob domain peptides
JP2023550548A (en) * 2020-11-10 2023-12-01 アビラマックス・バイオファーマ・インコーポレイテッド Engineered viral capsids and methods of use

Also Published As

Publication number Publication date
TW202507010A (en) 2025-02-16
KR20260034663A (en) 2026-03-11
WO2025008323A1 (en) 2025-01-09
AU2024290842A1 (en) 2026-01-15
CN121712809A (en) 2026-03-20
AR133153A1 (en) 2025-09-03

Similar Documents

Publication Publication Date Title
PL4211231T3 (en) Peptide-modified aav capsid
IL275838A (en) A modified raav capsid protein for gene therapy
IL316719A (en) Aav capsid variants and uses thereof
IL314156A (en) Aav capsid variants and uses thereof
IL286831A (en) Adeno-associated virus with engineered capsid
IL276859A (en) Novel adeno-associated virus (aav) vectors, aav vectors having reduced capsid deamidation and uses therefor
IL276860A (en) Novel adeno-associated virus (aav) vectors, aav vectors having reduced capsid deamidation and uses therefor
IL286725A (en) Engineered adeno-associated (aav) vectors for transgene expression
IL304688A (en) Adeno-associated virus (aav) production
EP4019642A4 (en) ISOLATED MODIFIED VP1 CAPSID PROTEIN FROM AAV5
EP4013770A4 (en) Aav capsid variants for gene therapy
IL307957A (en) Aav capsids and uses thereof
GB201915905D0 (en) Viruses with modified capsid proteins
SI3999119T1 (en) Modified aav capsid proteins for treatment of arthritic disease
IL325384A (en) Engineered aav capsid proteins
EP3987028A4 (en) Engineered oncoselective protein expression
CA3296068A1 (en) Engineered aav capsid proteins
GB202304767D0 (en) Synthetic AAV Capsid
HK40091751B (en) Peptide-modified aav capsid
HK40087446A (en) Adeno-associated virus with engineered capsid
HK40072859A (en) Engineered adeno-associated virus capsids
HK40076701A (en) Aav capsid variants for gene therapy
CA3290793A1 (en) Aav capsid variants and uses thereof
AU2023902317A0 (en) Modified cardiotropic aav capsid polypeptides and vectors
HK40123858A (en) Aav capsid variants and uses thereof